Miltefosine
Impavido (miltefosine) is a small molecule pharmaceutical. Miltefosine was first approved as Impavido on 2014-03-19. It is used to treat cutaneous leishmaniasis, leishmaniasis, and visceral leishmaniasis in the USA. It is known to target RAC-alpha serine/threonine-protein kinase.
Trade Name | Impavido |
---|---|
Common Name | Miltefosine |
Indication | cutaneous leishmaniasis, leishmaniasis, visceral leishmaniasis |
Drug Class | Phosphoro-derivatives |